Cabaletta Bio (MEX:CABA) Total Liabilities: MXN808.60 Mil (As of Mar. 2026)


MEX:CABA Cabaletta Bio Inc MEX:CABA
14 GF Score
Price MXN54.50
! 1 Warning Sign
View Full Analysis

What is Cabaletta Bio Total Liabilities?

Cabaletta Bio MEX:CABA 14 Total Liabilities is MXN808.60 Mil as of Mar. 2026. GuruFocus rates MEX:CABA with a GF Score™ of 14/100. The stock has 1 warning sign investors should review.

Cabaletta Bio's Total Liabilities for the quarter that ended in Mar. 2026 was MXN808.60 Mil.

Cabaletta Bio's quarterly Total Liabilities increased from Sep. 2025 (MXN922.59 Mil) to Dec. 2025 (MXN954.88 Mil) but then declined from Dec. 2025 (MXN954.88 Mil) to Mar. 2026 (MXN808.60 Mil).

Cabaletta Bio's annual Total Liabilities increased from Dec. 2023 (MXN296.24 Mil) to Dec. 2024 (MXN682.21 Mil) and increased from Dec. 2024 (MXN682.21 Mil) to Dec. 2025 (MXN954.88 Mil).

Cabaletta Bio Total Liabilities Historical Data

* Premium members only.

The historical data trend for Cabaletta Bio's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cabaletta Bio Total Liabilities Chart

Cabaletta Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only 171.91 242.69 296.24 682.21 954.88

Cabaletta Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 891.73 866.50 922.59 954.88 808.60
MEX:CABA
14GF Score
Cabaletta Bio Inc MEX:CABA
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cabaletta Bio Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Cabaletta Bio's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=903.04+(51.838+7.8159700933611E-14
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=954.88

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=2972.435-2017.557
=954.88

Cabaletta Bio's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=748.483+(60.121+9.2370555648813E-14
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=808.60

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=2671.472-1862.868
=808.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of MXN808.60 Mil mean?
Cabaletta Bio (MEX:CABA) has a Total Liabilities of MXN808.60 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Cabaletta Bio and its competitors.
Is Cabaletta Bio's Total Liabilities too high?
Cabaletta Bio's current Total Liabilities is MXN808.60 Mil. Overall, Cabaletta Bio has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Cabaletta Bio's Total Liabilities compare to RZLT and CCCC?
Cabaletta Bio's Total Liabilities of MXN808.60 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Cabaletta Bio and its competitors. Cabaletta Bio's current Total Liabilities is MXN808.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cabaletta Bio stock overvalued right now?
Cabaletta Bio (MEX:CABA) has a current Total Liabilities of MXN808.60 Mil. The current Total Liabilities is MXN808.60 Mil. Cabaletta Bio's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Cabaletta Bio (MEX:CABA), the current Total Liabilities is MXN808.60 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cabaletta Bio Business Description

Other Exchanges CABA:USA
Address 2929 Arch Street, Suite 600, Philadelphia, PA, USA, 19104
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
14GF Score

Get the complete analysis for MEX:CABA

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN54.50
Price